A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction
Sponsor: Charite University, Berlin, Germany
A PHASE2 clinical study on Chronic Heart Failure, this trial is completed. The trial is conducted by Charite University, Berlin, Germany and has accumulated 8 data snapshots since 2016. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
May 2017 — Oct 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — May 2017 [monthly]
Recruiting PHASE2
First recorded
Sep 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Charite University, Berlin, Germany
- SCIRENT Clinical Research and Science d.o.o.
- Stealth BioTherapeutics Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Belgrade, Serbia
- • Berlin, Germany
- • Kamenitz, Serbia
- • Niš, Serbia